

CNMV  
Edison, 4  
28006 Madrid

Barcelona (Spain), March 30, 2023

## OTHER RELEVANT INFORMATION

In accordance with Article 227 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, **LABORATORIO REIG JOFRE SA** ("Reig Jofre" or "the Company"), informs that the Ordinary and Extraordinary General Shareholders' Meeting was held upon the first call on 30 de March 30, with the agenda established and present shareholders owning 80,66% of share capital.

All resolutions were adopted by the legal and statutory majorities, being the following:

1. The individual and consolidated financial statements and the individual and consolidated management reports, the allocation of result obtained by the individual company during the year (€ 771,934.39) to the provision of the mandatory legal reserve for an amount of 77,193.44 euros and to voluntary reserves for an amount of 694,740.95 euros, and the conduct of business of the board of directors, all of that regarding the year 2022.
2. The Annual Report on Directors' Remuneration of the Company corresponding to the financial year 2022, with a consultative vote.
3. The resignation of REIG JOFRE INVESTMENTS, S.L. as member of the Board of Directors and of the Appointments, Remuneration and Sustainability Committee and, appointment of Ms Isabel Reig López as a new Company director.
4. Re-election of the following members of the Company's Board of Directors: Mr. Alejandro Garcia Reig, Ms. María Luisa Francolí Plaza, Mr. Ramón Gomis de Barbarà, Mr. Ramiro Martínez-Pardo del Valle, Mr. Emilio Moraleda Martínez y Mr. Ignasi Biosca Reig.



5. Re-election of the auditors of the Company and its Consolidated Group KPMG Auditores, S.L., for 2023.
6. Within "Reig Jofre Flexible Dividend" plan, an increase in the Company's share capital with a charge to reserves for an amount determined in accordance with the terms of the agreement, through the issuance of new ordinary shares with a nominal value of fifty cents and with provision for incomplete allocation. Offer to shareholders for the purchase of their preferential subscription rights for a guaranteed price. Request for admission to trading of issued shares. Delegation of powers to the Board of Directors, with express power of substitution, for the specification of the details concerning said capital increase. The sum of the reference market value of the New Shares, in accordance with the agreement, will have a maximum limit of € 3,215,327.30.
7. The board of directors, with express power of substitution, were granted powers for the formalization, interpretation, correction and/or implementation of the agreements adopted by the General Shareholders Meeting.

Yours faithfully,

Mr. Adolf Rousaud  
Secretary non-director of the Board of Directors